Clinical Trial Update: Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ICP-490 in relapsed/refractory multiple myeloma across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ICP-490

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Relapsed and/or Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN